WAVE Life Sciences (WVE) Misses Q2 EPS by 18c, Revenues Miss

WAVE Life Sciences (NASDAQ: WVE) reported Q2 EPS of ($1.15), $0.18 worse than the analyst estimate of ($0.97). Revenue for the quarter came in at $3.03 million versus the consensus estimate of $5.65 million.

“In the second quarter, despite persistent global challenges due to the COVID-19 pandemic, we continued to execute on our clinical and preclinical neurology programs. Our clinical, laboratory and manufacturing teams have proven to be adaptable and resilient as they work amidst new operating environments,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “We are on track to submit clinical trial applications for our C9orf72 program for amyotrophic lateral sclerosis and frontotemporal dementia and our SNP3 program for HD in the fourth quarter of this year, both of which are designed with a novel chemistry application from our PRISM platform. During our upcoming Analyst & Investor Research Webcast on August 25, we plan to share exciting updates on our platform, including advances in oligonucleotide chemistry and our promising ADAR editing modality, and new preclinical data for our C9orf72 program.”

For earnings history and earnings-related data on WAVE Life Sciences (WVE) click here.

You May Also Be Interested In

• Keurig Dr Pepper coffee chief to depart ahead of planned split
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• AXT appoints Tracy Liu to its board of directors